Sahajanand Medical Technologies IPO Listing Price, GMP History

IPO overview

Sahajanand Medical Technologies designs and builds minimally invasive cardiovascular equipment for global healthcare markets. The enterprise initiated an initial public offering on October 15, 2026, structured completely as an offer for sale to provide liquidity for existing holders.

About the company

The organization manufactures a comprehensive selection of medical apparatus centered on vascular and structural heart therapies. Primary product lines feature coronary intervention devices incorporating specialized biodegradable polymer coating technology, such as the Supraflex Cruz, Tetriflex, Tetrilimus, and Supraflex Star stent variants. Furthermore, the catalogue delivers PTCA balloon dilatation catheters including the Wilma and Pipit families, alongside supportive accessories such as aspiration and haemostatic instruments.

Beyond coronary care, the business supplies structural heart instruments featuring Cocoon septal, PFO, duct, and VSD occluders, accompanied by Hydra aortic valve solutions. Peripheral intervention apparatus includes balloon-expandable renal and biliary stent systems as well as drug-coated PTA balloons. Operating across seventy-six countries, the manufacturer utilizes strict quality-controlled production procedures and evidence-based clinical evaluations.

Company background source: Sahajanand Medical Technologies — company information · Checked 13 Oct 2026. This source covers the business description; GMP is an unofficial indication.